Centaurus Financial Inc. Takes Position in Pfizer Inc. $PFE

Key Points

• Centaurus Financial acquired 36,772 Pfizer shares during the second quarter, valued at approximately $885,000. Hedge funds and other institutional investors collectively own 68.36% of Pfizer’s stock.
• Analysts maintain a predominantly cautious outlook, with an average rating of “Hold” and an average price target of $28.28, close to Pfizer’s $27.95 share price.
• Pfizer exceeded quarterly earnings and revenue expectations and declared a $0.43 quarterly dividend, equivalent to a 6.2% yield; however, its 226.32% payout ratio raises concerns about dividend sustainability.

Centaurus Financial Inc. bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 36,772 shares of the biopharmaceutical company's stock, valued at approximately $885,000.

Several other institutional investors also recently bought and sold shares of PFE. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter valued at $26,000. Keb Asset Management LLC bought a new stake in Pfizer in the 2nd quarter worth $26,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $31,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Guggenheim lowered their price target on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Wolfe Research reiterated an "underperform" rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. UBS Group reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $28.28.

Pfizer Price Performance

Shares of NYSE PFE opened at $27.95 on Friday. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75. The stock has a market capitalization of $159.31 billion, a P/E ratio of 36.78 and a beta of 0.34. The company's 50-day moving average is $25.55 and its 200 day moving average is $26.30. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business posted $0.78 earnings per share. Pfizer's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. Pfizer's payout ratio is currently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source